Products / Other therapeutic lines
Yriviak
Bevacizumab 5 mg/0,2 ml
Yriviak is indicated for the treatment of adult patients with neovascular (exudative) age-related macular degeneration (AMD).
Therapeutic Action
Antiangiogenic agent, monoclonal antibody.
Presentations
Package with 1 vial containing 0.2 ml (5 mg) of bevacizumab solution and the following sterile disposable medical products: extraction filter needle (18G X 1½”, 1.2 mm x 40 mm, 5 µm filter), 1 ml syringe and injection needle (30G x ½”, 0.3 mm x 13 mm).
Download
Prospect